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ABSTRACT:
Epithelial ovarian cancer is a highly lethal and aggressive gynecological 
malignancy. The high mortality rate is due in part to the fact that many advanced 
cancer patients become refractory to current chemotherapeutic agents, leading 
to tumor recurrence and death. However, the underlying mechanisms leading to 
chemoresistance remain obscure. Here, we report that the loss of miR-199b-5p due to 
progressive epigenetic silencing leads to the activation of the JAG1-mediated Notch1 
signaling cascade, thereby leading to the development of acquired chemoresistance 
in ovarian cancer. Using miRCURY LNATM microRNA array and Q-PCR analyses of two 
pairs of cisplatin-sensitive and –resistant ovarian cancer cell lines, we identified 
miR-199b-5p as significantly down-regulated in cisplatin-resistant ovarian cancer 
cells and confirmed that miR-199b-5p is clinically associated with advanced and poor 
survival ovarian cancers. Interestingly, the loss of miR-199b-5p could be restored by 
5-Aza-dC-mediated demethylation, and methylated specific PCR (MS-PCR), bisulfite-
sequencing and pyrosequencing revealed that the promoter region of miR-199b-5p 
was hypermethylated. Computational and mechanistic analyses identified JAG1 as 
a primary target of miR-199b-5p. Notably, the reduced expression of miR-199b-5p 
was found to be inversely correlated with the increased expression of JAG1 using an 
ovarian cancer tissue array. Enforced expression of miR-199b-5p sensitized ovarian 
cancer cells to cisplatin-induced cytotoxicity both in vitro and in vivo. Conversely, re-
expression of miR-199b-5p and siRNA-mediated JAG1 knockdown or treatment with 
Notch specific inhibitor γ-secretase (GSI) attenuated JAG1-Notch1 signaling activity, 
thereby enhancing cisplatin-mediated cell cytotoxicity. Taken together, our study 
suggests that the epigenetic silencing of miR-199b-5p during tumor progression is 
significantly associated with acquired chemoresistance in ovarian cancer through the 
activation of JAG1-Notch1 signaling. 
INTRODUCTION:
Epithelial ovarian cancer is one of the most lethal 
malignancies in females worldwide. The high mortality 
rate of this disease is due to its poor prognosis and 
the fact that the majority of patients are diagnosed at 
advanced stages. Therefore, chemotherapy combined with 
surgical cytoreduction is the standard initial management 
for ovarian cancer patients at advanced stages [1, 2]. 
Platinum-based chemotherapy is the standard first-line 
regimen for advanced ovarian cancer [3, 4]. The clinical 
response rate is initially high, but the subsequent relapse 
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and repetitive challenges of chemotherapeutic agents 
leads to the development of acquired chemoresistance 
[5]. Such acquired chemoresistance is the major obstacle 
to the clinical management of ovarian cancer [6, 7]. 
However, the molecular mechanisms underlying acquired 
chemoresistance remain largely unknown, underlying 
the urgent need to identify the associated molecular 
mechanisms to explore alternative therapeutic strategies.
Acquired chemoresistance, also called as extrinsic 
chemoresistance, develops secondary to genetic and 
epigenetic alterations in cell proliferation, apoptosis, 
DNA repair, etc., after the administration of repetitive 
cycles of chemotherapy [5, 8, 9]. Genetic changes refer 
to the changes in the DNA sequence, including mutation, 
deletion, amplification, and translocation, whereas 
epigenetic alterations include DNA methylation, histone 
modifications and microRNA (miRNA) regulation. 
Emerging evidence suggests the importance of miRNAs 
in developing acquired chemoresistance in various human 
cancers [10-12]. The dysregulation of miRNAs alters 
a network of functional targets and signaling pathways, 
resulting in acquired chemoresistance in human cancers 
[10, 11]. For examples, up-regulation of miR-21 causes 
acquired trastuzumab resistance by repressing PTEN 
expression during long-term exposure to trastuzumab 
antibody in breast cancer [13], and the repetitive 
application of cisplatin (CDDP) to non-small cell lung 
cancer (NSCLC) A549 cells induces an increase in miR-
630, which enhances cytoprotection against CDDP and 
carboplatin by inhibiting the p53 signaling pathway 
[14]. This evidence prompted us to hypothesize that 
some miRNAs may be involved in developing acquired 
chemoresistance during ovarian cancer progression.
In this study, we used the miRCURY LNATM 
microRNA Array followed by a series of in vitro and in 
vivo functional and biochemical analyses to identify miR-
199b-5p as being associated with cisplatin resistance 
in ovarian cancer cells. Importantly, our finding 
provides a novel molecular mechanism of epigenetic-
mediated acquired chemoresistance in ovarian cancer 
by which miR-199b-5p is frequently silenced by DNA 
hypermethylation, thereby leading to the activation of 
JAG1-Notch1 signaling in ovarian cancer progression and 
acquired chemoresistance. 
RESULTS:
Identification of miR199b-5p as a putative miRNA 
candidate involved in the chemoresistance of 
ovarian cancer
To investigate the dysregulated miRNAs in ovarian 
cancer with acquired chemoresistance, microRNA 
profiling was performed using the miRCURY LNATM 
miRNA array on two pairs of ovarian cancer cell lines 
(cisplatin-sensitive: A2780s and OV2008 vs. cisplatin-
resistant: A2780cp and C13*) [15]. Our results revealed 
that there were 35 upregulated miRNAs (>2-fold) and 
45 downregulated miRNAs (<0.5-fold) with statistical 
significance (data not shown). Among these dysregulated 
miRNAs, 21 upregulated miRNAs and 10 downregulated 
miRNAs were commonly found in both pairs of cell lines 
(Supplementary Fig. S1). In this study, the downregulated 
miRNAs in chemoresistant ovarian cancer cells were 
studied. Of 10 downregulated miRNAs, 5 miRNAs 
(miR-10b, miR-99a, miR-193a-3p, miR-199b-5p and 
miR-675) were selected for verification of the response 
to cisplatin-induced cell cytotoxicity via transient 
transfection of their pre-miRNA-expressing plasmids. 
Among these 5 candidates, XTT cell proliferation assay 
demonstrated that miR-199b-5p exhibited a remarkable 
Fig 1: Loss of miR199b-5p is involved in acquired 
chemoresistance and advanced-stage ovarian cancer. 
(A) miR-199b-5p expression was measured by quantitative RT-
PCR in a panel of ovarian cancer cell lines: A2780s, A2780cp, 
OV2008, C13*, SKOV3, OVCA429, OVCA433, and ES-2. 
The results are reported as the mean ± SD of three independent 
experiments performed in triplicate, ** P<0.01. (B) Comparison 
of miR-199b-5p expression in early-stage (Stage I, N=28) vs. 
advanced-stage (Stage II, III and IV, N =51) ovarian cancer 
(P=0.047) and in low-grade vs. high-grade disease as determined 
by Q-PCR. (C) Comparison of the survival curve of ovarian 
cancer patients with high (n=12) and low levels (n=51) of miR-
199b-5p. The relative expression level of miR-199b-5p (0.024) 
was used as a cutoff point. * P = 0.047
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increase in the cisplatin-mediated cell cytotoxicity of 
A2780cp and C13* cells (data not shown). As miR-
199b-5p could sensitize ovarian cancer cells to cisplatin-
induced cytotoxicity, we hypothesized that the loss of the 
miR-199b-5p is involved in chemoresistance of ovarian 
cancer. To validate this hypothesis, Q-PCR was performed 
to evaluate the expression of miR-199b-5p. We confirmed 
that miR-199b-5p was downregulated in chemoresistant 
ovarian cancer cells A2780cp and C13* compared with 
their chemosensitive counterparts A2780s and OV2008 
(Fig. 1A). In addition to these cell lines, the expression 
of miR-199b-5p was also reduced in other chemoresistant 
ovarian cancer cell lines: SKOV3, OVCA433 and ES-2 
[16-18] (Fig. 1A). We observed a trend of progressively 
diminishing miR-199b-5p expression (measured as 2-ΔCt) 
from early to advanced stages and from low to high grade 
ovarian cancer (Fig. 1B). Importantly, the downregulated 
miR-199b-5p was significantly correlated with poor 
survival rate (P=0.047) (Fig. 1C). These results indicate 
that the expression of miR-199b-5p is gradually silenced in 
ovarian cancer progression and that downregulated miR-
199b-5p is significantly associated with chemoresistance 
and poor survival of ovarian cancer patients. 
Loss of miR-199b-5p is attributed to promoter 
hypermethylation in ovarian cancer
 Recent evidence suggests that DNA methylation 
typically silences expression of miRNAs in cancer 
progression [19, 20]. To investigate whether the 
downregulation of miR-199b-5p was attributed to 
Fig 2: Hypermethylation silences miR-199b-5p expression in ovarian cancer. (A) The expression of miR-199b-5p could be 
restored in cisplatin-resistant ovarian cell lines upon 5-Aza-dC mediated demethylation treatment (*P<0.05, ** P<0.01). (B) Schematic 
illustration of CpG islands in the promoter region of miR-199b-5p. Vertical lines indicate CpG sites. The arrows indicate the MS-PCR, 
BGS and pyrosequencing (-6318 to -6228) regions. (C) Promoter methylation status of miR-199b-5p was evaluated by MS-PCR in ovarian 
cancer cells upon treatment of 5-Aza-dC-mediated demethylation. (D) BGS evaluation of the promoter methylation status of miR-199b-
5p in ovarian cancer cells A2780s, A2780cp and SKOV3 with/without 5-Aza-dC mediated demethylation. Each row of circles indicates a 
single clone. Each circle indicates a CpG site. Filled, methylated CpG site. Unfilled, unmethylated CpG site. (E) Pyrosequencing analysis 
revealed that methylation density of ovarian cancer cell lines. (F) Pyrosequencing results of ovarian cancer samples indicated that there was 
a progressive increase in the methylation status with tumor stage (stage 3 vs. stage 2, P=0.0482; stage 4 vs. stage 2, P=0.0412), whereas 
there was no significance relationship between the methylation status and tumor grade. Each dot represents the methylation percentage of 
each clinical sample.
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promoter hypermethylation in ovarian cancer, 6 ovarian 
cancer cell lines were treated with the DNA demethylation 
reagent 5-Aza-2’-deoxycitidine (5-Aza-dc). Q-PCR 
analysis demonstrated that the expression of miR-199b-
5p was significantly restored in 5 out of 6 ovarian cancer 
cell lines after 5-Aza-dc mediated demethylation (Fig. 
2A). Further analysis of the methylation status of the 
promoter region of miR-199b-5p was performed by 
bisulfite genomic sequencing (BGS) and methylation-
specific PCR (MS-PCR). A CpG island located -6,500 to 
-5,000 bp upstream of pre-miR-199b was identified (Fig. 
2B). MS-PCR and BGS were employed to evaluate the 
DNA methylation status within the CpG islands of the 
promoter region of miR-199b-5p in ovarian cancer cell 
lines. The MS-PCR results revealed that an increase in 
DNA methylation was frequently observed in the promoter 
region of miR-199b-5p in chemoresistant ovarian cancer 
cell lines (A2780cp, C13* and OVCA433), whereas 
increased DNA methylation status could be reversed 
with 5-Aza-dc treatment (Fig. 2C). In contrast, less DNA 
methylation was observed in chemosensitive A2780s 
cells and in SKOV3 cells in which the expression of miR-
199b-5p could not be restored by 5-Aza-dc demethylating 
activity (Fig. 2C). The DNA methylation status of the 
miR-199b-5p promoter was further validated by BGS and 
pyrosequencing analyses, and the results were consistent 
with the above findings (Figs. 2D and 2E). In clinical 
samples, pyrosequencing analysis also revealed that DNA 
methylation was gradually increased in parallel with the 
tumor stage (Stage 2 vs. Stage 3, P = 0.0482; Stage 2 vs. 
Stage 4, P = 0.0412) (Fig. 2F). However, due to the small 
patient cohort, a significant correlation between DNA 
methylation and tumor grade could not be found (Fig. 2F). 
Collectively, these data suggest that the downregulation of 
miR-199b-5p is attributed to increased DNA methylation 
during repetitive chemotherapeutic challenges and ovarian 
cancer progression.
Fig 3: MiR-199b-5p sensitizes chemoresistant ovarian cancer cells to cisplatin-induced cytotoxicity in vitro and in 
vivo. (A) XTT cell proliferation assay revealed that ectopic expression of miR-199b-5p significantly reduce cell viability from 95-99% to 
80-85% in A2780cp, C13*, SKOV3 and ES-2 cells upon cisplatin treatment (3 μg/ml, 24 hours). (B) XTT cell proliferation assay revealed 
that depletion of miR-199b-5p increased cell viability from 11% to 25% in A2780s cells and 12% to 88% in OV2008 upon cisplatin 
treatment (1 μg/ml) at 24 h and 72 h compared with the negative control. (C & D) XTT cell proliferation assay demonstrated that the 
stable expression of miR-199b-5p inhibited cell proliferation by 15% in A2780cp cells and 13% in SKOV3 cells but further inhibited the 
cell viability 19-26% in A2780cp and 13-18% in SKOV3 upon cisplatin treatment (3 μg/ml). (E) The focus formation assay revealed that 
stable expression of miR-199b-5p caused a 40% reduction in foci formation in C13* and SKOV3 cells and an 80% reduction in A2780cp 
cells upon cisplatin treatment (3 μg/ml, 14 days). The results are reported as the mean ± SD of three independent experiments performed 
in triplicate, *, P<0.05, **, P<0.01. (F) miR-199b-5p stable expression (C2) and vector control C13* cells were inoculated subcutaneously 
into nude mice. The mice were i.p. injected with cisplatin (5 mg/kg) every three days beginning on day 7 when the palpable tumor was 
formed. The tumor size was calculated and reported as the mean tumor volume ± SE of each group of five mice. The miR-199b-5p stable 
expression transfectant (C2) resulted in a significantly slower tumor growth rate compared with the vector control. Vertical arrows indicate 
the time of cisplatin injection. Points, mean of 5 mice. Bars, SD. N=5, ** P<0.01. 
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Loss of miR199b-5p is associated with cisplatin-
resistant ovarian cancer cells
To study the functional role of miR-199b-5p in the 
chemoresistance of ovarian cancer, the pre-miR-199b-
5p expression plasmid (pmR-ZsGreen1-miR-199b-5p) 
was transiently transfected into five chemoresistant 
ovarian cancer cells (A2780cp, C13*, SKOV3, ES-2 and 
OVCA433). Upon treatment with cisplatin (3 μg/ml), 
the XTT cell proliferation assay revealed that enforced 
expression of miR-199b-5p significantly reduced cell 
viability by 15-20% in A2780cp, C13*, SKOV3 and ES-2 
cells compared with their vector controls (Fig. 3A). In 
contrast, depletion of miRNA-199b-5p in A2780s and 
OV2008 by a specific miRNA inhibitor (Ambion Product 
ID, AM10553) (Supplementary Fig. S2a) dramatically 
increased cell viability from 25% to 88% in A2780s and 
OV2008 cells, respectively, compared with their controls 
upon cisplatin treatment (Fig. 3B). 
To study whether miR-199b-5p is functionally 
relevant in the inhibition of ovarian cancer cell growth, 
stable expression of miR-199b-5p in A2780cp and SKOV3 
cells (Supplementary Fig. S2B) was observed suppressed 
cell proliferation by 15% in A2780cp and by 13% in 
SKOV3 cells (Fig. 3C). Furthermore, upon treatment 
with cisplatin, the miR-199b-5p stably expressing cells 
in A2780cp (C4) and SKOV3 (C2) exhibited reduced 
cell viability, approximately 15-20% compared with the 
vector controls (Fig. 3D). By focus formation assay, the 
miR-199b-5p stably expressing cells (A2780cp C3 and 
C4, C13* C1 and C2, SKOV3 C1 and C2) exhibited 40-
80% reduced foci formation in both number and size upon 
cisplatin treatment (Fig. 3E) (Supplementary Fig. S2C). 
These results indicate that miR-199b-5p is capable of 
suppressing ovarian cancer cell growth and sensitizing 
ovarian cancer cells to be cisplatin-induced cytotoxicity.
To confirm the role of miR-199b-5p in enhancing 
the sensitivity of ovarian cancer cells to cisplatin-mediated 
cytotoxicity in vivo, the miR-199b-5p stably expressing 
ovarian cancer cell C13* (C2) and vector control were 
subcutaneously (s.c.) injected into the right and left flanks 
of mice, respectively. The tumor-bearing mice were then 
treated with 5 mg/kg cisplatin every three days beginning 
on Day 7. On Day 19, the size of tumor from the miR-
199b-5p expressing cells was profoundly smaller (~70%) 
than the vector control (Fig. 3F). Taken together, these 
data suggest that the loss of miR-199b-5p is associated 
with increased tumor growth and the cisplatin resistance 
of ovarian cancer cells. 
JAG1 is a direct target of miR199b-5p in ovarian 
cancer
To identify the potential targets regulated by miR-
199b-5p, bioinformatic databases such as TargetScan 
and miRanda were searched. Among the list of potential 
targets, JAG1 was identified as a target of miR-199b-5p. 
JAG1 contains a highly conserved miR-199b-5p binding 
site at nucleotides 135—141 in its 3’UTR and is a trans-
membrane protein acting as a key ligand of Notch receptors 
in ovarian cancer [16, 21]. To further prove whether 
JAG1 acts as a primary target of miR-199b-5p, luciferase 
reporter plasmids containing the JAG1 3’UTR wild-type 
binding sites pmirGLO-JAG1-3’UTR-WT (ACACUGG) 
and the mutated binding sites pmirGLO-JAG1-3’UTR-
MUT (TCTCAGG) (Fig. 4A) were constructed and co-
transfected with an miR-199b-5p mimic (pmR-ZsGreen1-
miR-199b-5p) in HEK293 cells. The result demonstrated 
that co-transfection of pmirGLO-JAG1-3’UTR-WT and 
pmR-ZsGreen1-miR-199b-5p could reduce luciferase 
activity by 38% compared with the vector control. In 
contrast, co-transfection of pmirGLO-JAG1-3’UTR-MUT 
and pmR-ZsGreen1-miR-199b-5p exhibited no difference 
in luciferase activity compared with the vector control 
(Fig. 4B). Moreover, western blot analysis revealed that 
the expression of JAG1 was upregulated and was inversely 
associated with the decreased expression level of miR-
199b-5p in ovarian cancer cell lines such as C13*, SKOV3 
and ES-2 (Fig. 4C). Enforced expression of miR-199b-5p 
significantly and dose dependently reduced the expression 
of JAG1 in HEK293 cells as well as in two chemoresistant 
ovarian cancer cell lines, C13* and SKOV3 (Fig. 4D). 
Intriguingly, the enforced expression of miR-199b-5p 
profoundly reduced HES1 luciferase reporter activity in 
SKOV3 cells by 35% (Fig. 4E), indicating the JAG1-
Notch1 signaling cascade could be suppressed by miR-
199b-5p in ovarian cancer cells. These findings suggest 
that JAG1 is a direct target of miR-199b-5p and that 
reduced miR-199b-5p and increased JAG1 are involved 
in ovarian cancer chemoresistance.
To verify whether the upregulation of JAG1 
was attributed to the loss of miR-199b-5p in 
ovarian cancer, both in situ hybridization (ISH) and 
immunohistochemistry (IHC) were performed to 
examine the expression level of miR-199b-5p and JAG1, 
respectively, on a commercial human ovarian cancer tissue 
array (OVC1021, Pantonmics). The results revealed that 
low expression of miR-199b-5p (≤2-fold) was significantly 
correlated with high expression of JAG1 (>5-fold) (Fig. 
4F, N=97, P=0.013). Intriguingly, clinicopathological 
analysis revealed that both low expression of miR-199b-
5p (≤2-fold) and high expression of JAG1 (>5-fold) were 
significantly correlated with high-grade tumors (p=0.014 
for miR-199b-5p and P<0.001 for JAG1) (Table 1). These 
results further indicate that the downregulation of miR-
199b-5p contributes to the upregulation of JAG1 and is 
involved in aggressive ovarian cancer, such as high-grade 
tumors.
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JAG1 is required for ovarian cancer cell growth 
and cisplatin-induced cytotoxicity
Aberrant upregulation of JAG1 has been reported 
to be associated with human cancer development and 
progression [16, 22, 23]. To study the function of JAG1 
in ovarian cancer oncogenesis and chemoresistance, we 
evaluated the expression of JAG1 on a panel of ovarian 
cancer cell lines. Western blot analysis demonstrated 
that JAG1 was upregulated in most ovarian cancer cell 
lines (Fig. 4C). Intriguingly, higher JAG1 expression was 
exclusively observed in cisplatin–resistant ovarian cancer 
cell lines (C13*, SKOV3 and A2780cp) compared with 
their corresponding cisplatin-sensitive cell lines (OV2008 
and A2780s) (Fig. 4C). A long exposure time in western 
blotting revealed that A2780cp cells exhibited a higher 
expression level of JAG1 than did A2780s (Supplementary 
Fig 4: JAG1 is a direct target of mir199b-5p and a key factor mediating Notch1 signaling activity in chemoresistant 
ovarian cancer. (A) A schematic diagram indicating the wild-type and mutated type binding sites of miR-199b-5p in the JAG1 3’UTR. 
(B) The luciferase reporter assay demonstrated that co-transfection of the JAG1 3’UTR wild-type pmir-GLO-JAG1-WT but not the mutated 
pmirGLO-JAG1-MUT plasmids (100 ng) with pmR-ZsGreen1-miR-199b-5p (400 ng) resulted in a 38% reduction in the luciferase activity 
compared with the vector control. *, P=0.025. (C) Both western blot and Q-PCR results indicated a reciprocal expression pattern of JAG1 
and miR-199b-5p in a panel of ovarian cancer cell lines. (D) Transient transfection of pmR-ZsGreen1-miR-199b-5p reduced the expression 
of JAG1 in HEK293 cells in a dose–dependent manner and in chemoresistant C13* and SKOV3 cells. (E) Co-transfection of miR-199b-5p 
reduced HES1 luciferase activity by 35% compared with the vector control in SKOV3, expressing a relatively higher level of JAG1. (F) 
Representative pictures showing an inverse relationship between the expression levels of miR-199b-5p and JAG1 examined by ISH and 
IHC analyses in a commercial ovarian cancer tissue array (OVC1021, N=97, P=0.013). Two-fold and 5-fold changes in expression were 
used as cutoff level for miR-199b-5p and JAG1, respectively, in the statistical analysis.
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Fig. S3A). Importantly, the higher expression of JAG1 in 
A2780cp was accompanied by higher levels of Notch1, 
suggesting that Notch1 signaling activity was higher 
in A2780cp (Supplementary Fig. S3B). To examine 
the effect of JAG1 on cisplatin-resistance, one of the 
cisplatin-sensitive ovarian cancer cell lines, A2780s, was 
transiently transfected with JAG1 at variable doses (0.5, 
1.0, and 2.0 µg) (Fig. 5A). An XTT cell proliferation 
assay revealed that enforced expression of JAG1 could 
significantly increase the cell proliferation rate by 29% 
and enhance the cell viability by 40% upon treatment 
with cisplatin compared with the vector control (Fig. 
5B). Conversely, two chemoresistant cell lines, C13* and 
SKOV3, expressing a relatively higher level of JAG1 
were selected for siRNA-mediated knockdown. An XTT 
cell proliferation assay indicated that the cell viability was 
remarkably reduced by 15-20% in C13* cells and by 10-
15% in SKOV3 cells upon cisplatin treatment compared 
with their scrambled controls (Fig. 5C). These data suggest 
that JAG1 could enhance the cell proliferation and cell 
viability of ovarian cancer cells to cisplatin-induced cell 
cytotoxicity.
JAG1 enhances the chemoresistance of ovarian 
cancer cells by activating Notch1 signaling activity
JAG1 acts as a key ligand of the Notch1 receptor 
in cancer development [22, 24, 25]. More importantly, 
Notch1 signaling has been shown to be involved in 
chemoresistance in numerous human cancers [26-
Table 1: Clinicopathological correlation of 
the expression of JAG1 in an ovarian cancer 
tissue array (OVC1021)
Parameters n(=97)
JAG1 expression
≤5-fold >5-fold p-value
Grade
Low (1+2) 50 23 (46%) 27 (54%)
High (3) 46 4 (9%) 42 (91%) <0.001*
Stage
Early (1+2) 73 18 (25%) 55 (75%)
Late (3) 24 10 (42%) 14 (58%) 0.126
Metastasis
Yes 24 11 (46%) 13 (54%)
No 73 17 (23%) 56 (77%) 0.042*
Fig 5: JAG1 enhances ovarian cancer cell growth and cisplatin-resistance. (A) Western blot analysis demonstrating the 
transient transfection of JAG1 (pCD-HA/JAG1) in A2780s cells. (B) XTT cell proliferation assay demonstrated that enforced expression of 
JAG1 increased the cell proliferation rate by 29% and increased cell viability by up to 40% in A2780s cells upon cisplatin treatment (1 μg/
ml). (C) Western blot analysis revealed that two out of three siRNAs (siRNA2 and siRNA3) remarkably reduced JAG1 expression by 80-
85% in C13* and 70-75% in SKOV3 cells compared with scrambled controls (NC) (left panel). XTT cell proliferation assay demonstrated 
that depletion of JAG1 by siRNA reduced cell viability by 15-20% in C13* cells and 10-15% in SKOV3 cells upon cisplatin treatment (3 
μg/ml) (right panel). The results are expressed as the mean ± SD of three independent experiments performed in triplicate. *, P<0.05, **, 
P<0.01.
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28]. Hence, we speculated that JAG1-mediated 
Notch1 signaling activity is involved in ovarian cancer 
oncogenesis and chemoresistance. To this end, a luciferase 
reporter assay for the JAG1 expression plasmid (pCD-HA/
JAG1) and the HES1 luciferase reporter plasmid (pHES1-
luc) [29] was performed in OV2008 cells. HES1 is a well-
known downstream target of the Notch1 receptor, and 
the activation of HES1 represents the activity of Notch1 
signaling [30]. The luciferase reporter assay revealed that 
transient transfection of JAG1 (1 µg) increased HES1 
luciferase activity by 30% in OV2008 cells, suggesting 
that JAG1 is capable of activating Notch1 signaling 
Fig 6: JAG1 enhances the chemoresistance of ovarian cancer cells by activating Notch1 signaling activity. (A) HES1 
luciferase reporter assay demonstrated that JAG1 was able to increase HES1 luciferase activity by 30% compared with the vector control in 
OV2008. (B) Western blot analysis revealed that GSI inhibited the expression of the Notch1 active domain by 60-95% in A2780cp, C13*, 
SKOV3 and ES-2 cells. (C) XTT cell proliferation assay demonstrated that GSI or cisplatin reduced cell viability by 5-10% in A2780cp, 
C13*, SKOV3 and ES-2 cells after 24 to 72 hrs. Co-treatment with GSI and cisplatin dramatically reduced cell viability by 17-38% in the 
above cell lines after 24 hrs to 72 hrs when compared with the DMSO control. Dose of DMSO, 10 μM; GSI, 10 μM; cisplatin, 3 μg/ml; GSI, 
10 μM, + cisplatin, 3 μg/ml. The results are reported as the mean ± SD of three independent experiments performed in triplicate. *, P<0.05, 
**, P<0.01. (D) Blocking Notch1 signaling by GSI enhances cisplatin-mediated cell cytotoxicity in a tumor xenograft mouse model. ES-2 
cells were injected subcutaneously into nude mice. The tumor-bearing nude mice were separated into 4 test groups on day 7 and were i.p. 
injected with DMSO, GSI (200 ng/kg), cisplatin (5 mg/kg) or a combination of GSI and cisplatin every two days. The tumor size was 
monitored and calculated as the mean tumor volume ± SE of each group. The group receiving both GSI and cisplatin exhibited the slowest 
tumor growth rate. The representative picture shows the tumor size of each group. Vertical arrows indicate the time of drug injection. Points 
show the mean of 3 mice of each group. Bars, SD. N=3, * P<0.05; ** P<0.01.
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activity (Fig. 6A).
To further investigate the functional role of Notch1 
signaling in the chemoresistance of ovarian cancer, a 
γ-secretase inhibitor (GSI XXI, compound E, 10 μM) 
was used to inhibit Notch1 activity in the chemoresistant 
ovarian cancer cells A2780cp, C13*, SKOV3 and ES-2 
(Fig. 6B). Upon treatment with either GSI or cisplatin 
alone, there was a 5-10% reduction in the cell viability 
compared with the DMSO control in four ovarian cancer 
cell lines: A2780cp, C13*, SKOV3 and ES-2 cells (Fig. 
6C). However, when the cells were co-treated with 
GSI and cisplatin together, we observed the synergistic 
enhancement of cisplatin-induced cytotoxicity, with a 
17-38% reduction in the cell viability of all four ovarian 
cancer cell lines (Fig. 6C). To further explore whether 
blocking Notch1 signaling could enhance cisplatin-
mediated cell cytotoxicity in vivo, 5-week BALB/
cAnN nude mice were subcutaneously injected with the 
chemoresistant ovarian cancer cell line ES-2. When the 
tumors were palpable on Day 7, the mice were randomly 
divided into 4 groups. Each group was administered one 
treatment by intraperitoneal injection every two days: 
DMSO, GSI (200 μg/kg), cisplatin (5 mg/kg) or GSI (200 
μg/kg) combined with cisplatin (5 mg/kg). When the mice 
were treated with GSI or cisplatin alone, the tumor growth 
was inhibited by 20% and 45%, respectively, compared 
with DMSO group (Fig. 6D). However, co-treatment 
with GSI and cisplatin synergistically enhanced cisplatin-
induced cytotoxicity, resulting in a 73% reduction in 
tumor growth on day 18 (Fig. 6D). These results indicate 
that the JAG1/Notch1 signaling pathway is indispensable 
for cisplatin resistance in ovarian cancer cells.
DISCUSSION:
The acquisition of resistance during tumor 
progression and repeated challenges of chemotherapy 
is the major obstacle of clinical management of ovarian 
cancer [15, 31-33]. However, the underlying mechanisms 
leading to chemoresistance in ovarian cancer remain 
poorly understood. In this study, we identified that the loss 
of miR-199b-5p, mediated by increased DNA methylation, 
is associated with acquired cisplatin resistance via aberrant 
activation of JAG1-Notch1 signaling in ovarian cancer. 
Blocking the JAG1-Notch1 signaling axis by either re-
expression of miR-199b-5p, siRNA-mediated JAG1 
knockdown or treatment with the Notch-specific inhibitor 
γ-secretase (GSI) dramatically abrogated tumor growth 
and enhance cisplatin-induced cytotoxicity in vitro and in 
vivo in ovarian cancer cells. Our study provides a novel 
regulatory circuit in which the epigenetic machinery 
silences the expression of miRNAs to dysregulate the 
activity of the key signaling pathways involved in 
developing ovarian cancer chemoresistance. 
Mounting evidence has suggested that the 
dysregulation of miRNAs causes aberrant upregulation 
of oncogenes or the downregulation of tumor suppressor 
genes which in turn leads to cancer initiation and 
progression [34-36]. In this study, miR-199b-5p was 
identified as a downregulated miRNA from two pairs of 
cisplatin sensitive vs. resistant ovarian cancer cell lines 
(A2780s vs. A2780cp and OV2008 vs. C13*) [15, 37, 38]. 
The cisplatin-resistant cell lines A2780cp and C13* were 
obtained from repetitive challenges of cisplatin treatment 
to A2780s and OV2008 cells. This repeated challenge of 
cisplatin treatment mimics the clinical situation in which 
the patient is repeatedly treated by cisplatin before they 
are in recurrence [39]. Interestingly, the downregulation 
of miR-199b-5p was progressively enhanced from early 
to advanced stages and low- to high-grade ovarian 
cancer tissue samples, indicating that the loss of miR-
199b-5p is involved in ovarian cancer progression. 
Accumulating evidence has documented that aberrant 
genetic and epigenetic alterations always occur during 
cancer progression, including in the progression of ovarian 
cancer [40-42]. These alterations result in abnormal 
activation of functional signaling, which in turn leads to 
so-called “acquired chemoresistance”. Hence, acquired 
chemoresistance is proposed to be a dominant player in 
ovarian cancer [7, 43-45]. In this study, forced expression 
of miR-199b-5p could not only suppress ovarian cancer 
cell growth but also sensitize resistant ovarian cancer 
to cisplatin treatment in vitro and in vivo. These results 
suggest that miR-199b-5p plays a significant role in tumor 
suppression by inhibiting cell growth and enhancing the 
chemosensitivity of epithelial ovarian cancer. 
Table 2: Clinicopathological correlation of the 
expression of miR199b-5p in an ovarian cancer 
tissue array (OVC1021)
Parameters n(=97)
miR199b-5p expression
≤2-fold >2-fold p-value
Grade
Low (1+2) 50 18 (36%) 32 (64%)
High (3) 46 29 (63%) 17 (37%) 0.014*
Stage
Early (1+2) 73 38 (52%) 35 (48%)
Late (3) 24 10 (42%) 14 (58%) 0.482
Metastasis
Yes 24 10 (42%) 14 (58%)
No 73 38 (52%) 35 (48%) 0.482
JAG1
< 5 folds 28 8 (29%) 20 (71%)
> 5 folds 69 40 (58%) 29 (42%) 0.013*
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MiR-199b-5p was progressively downregulated 
from early to advanced stage and low- to high-grade 
ovarian cancer, suggesting that the loss of miR-199b-5p 
is the gradual result of epigenetic silencing mechanisms 
such as hypermethylation. Indeed, DNA hypermethylation 
has been frequently reported to silence tumor suppressor 
miRNAs in various human cancers, including ovarian 
cancer [46, 47]. For instance, downregulation of the miR-
34 family is induced by promoter hypermethylation and 
leads to the pathological progression of epithelial ovarian 
cancer [48]. Our results demonstrate that the expression of 
miR-199b-5p could be restored in 5 out of 6 ovarian cancer 
cell lines using 5-Aza-dC-mediated DNA demethylation. 
MS-PCR, BGS and pyrosequencing analyses further 
confirmed that an increase in the DNA methylation of the 
promoter of miR-199b-5p in ovarian cancer cell lines. 
More importantly, although there is a limited number of 
ovarian cancer samples for pyrosequencing analysis, our 
data suggests that there is a progressive increase in DNA 
methylation that is inversely correlated with the expression 
of miR-199b-5p during the progression of ovarian cancer. 
Therefore, these findings support our hypothesis that 
the loss of miR-199b-5p is attributed to increased DNA 
methylation during tumor progression and repetitive 
treatment of chemotherapy in ovarian cancer.
Dysregulation of the JAG1-Notch1 signaling 
cascade has been shown to activate a wide range of 
oncogenes in the HES, HEY and MYC families, thereby 
leading to ovarian cancer progression and chemoresistance 
[21, 49, 50]. Platinum-based chemotherapy is the 
standard first-line regimen for ovarian cancer patients 
with advanced-stage disease. Cisplatin is the most 
common platinum-based compound capable of causing 
inter- and intra-strand DNA crosslinks that induces cell 
apoptosis with DNA damage [51, 52]. Previous studies 
have proposed that the aberrant activation of the JAG1-
Notch1 signaling pathway may protect cancer cells from 
cisplatin-induced cell apoptosis and that the signaling 
activity is inversely correlated with the cisplatin sensitivity 
of human cancers [53-57]. Moreover, Notch signaling 
is associated with tumor growth and angiogenesis [58, 
59]. A recent study has suggested that the modulation 
of tumor angiogenesis by blocking VEGF signaling 
could reduce the chemoresistance of ovarian cancer 
[60], suggesting that JAG1/NOTCH1/neovascularization 
confers ovarian cancer chemoresistance. Indeed, our work 
provides compelling evidence that overexpressed JAG1 
could enhance ovarian cancer cell proliferation, whereas 
depletion of JAG1 by siRNAs or suppression of Notch1 
signaling by γ-secretase inhibitor (GSI) could sensitize 
chemoresistant ovarian cancer cells to cisplatin-induced 
cytotoxicity by in vitro and in vivo models, suggesting that 
the JAG1-Notch1 signaling axis plays a critical role in the 
development of ovarian cancer chemoresistance. 
Recent studies have reported that the expression of 
JAG1 is modulated by miRNAs. For instance, JAG1 could 
be repressed by miR-34b in estrogen-dependent breast 
cancer cells [61] and by miR-524-5p in glioma [62]. In 
this study, miR-199b-5p was identified as another novel 
miRNA regulating the expression of JAG1 in ovarian 
cancer. We demonstrated that the forced expression of 
miR-199b-5p could suppress ovarian cancer cell growth 
and sensitize the cells to cisplatin-induced cytotoxicity. 
On the other hand, as a direct target of miR-199b-5p in 
ovarian cancer cells, JAG1 depletion by siRNAs also 
resulted in cell growth retardation and sensitization to 
cisplatin-induced cytotoxicity. In contrast, activating 
Notch1 signaling by JAG1 or repressing miR-199b-5p 
by anti-miR-199b-5p could induce the activity of JAG1-
Notch1 signaling in ovarian cancer cells. Therefore, this 
study suggests that the loss of miR-199b-5p increased 
the activation of JAG1-Notch1 signaling, which in turn 
promoted ovarian cancer progression and acquired 
chemoresistance. Thus far, this is the first report, to our 
knowledge, that the miR-199b-5p-JAG1-Notch1 signaling 
pathway is a novel regulatory circuit for acquired 
chemoresistance in ovarian cancer. 
In conclusion, the findings in this study enhance 
our understanding of acquired chemoresistance in 
ovarian cancer during tumor progression or repetitive 
platinum-based chemotherapy. The epigenetic silencing 
of miR-199b-5p may at least partly activate JAG1-Notch1 
signaling activity and promote acquired chemoresistance 
in ovarian cancer. Therefore, targeting the miR-199b-5p-
JAG1-Notch1 regulatory circuit might be a therapeutic 
approach in cisplatin-resistant ovarian cancer.
MATERIALS AND METHODS:
Cell lines and clinical samples 
Ovarian cancer cell lines (A2780s, A2780cp, 
OV2008, C13*) (kindly provided by Prof. Benjamin 
K. Tsang, Department of Obstetrics and Gynecology, 
University of Ottawa), and SKOV3, OVCA433 and ES-2 
(purchased from American Type Culture Collection, 
ATCC) used in this study were grown at 37oC with DMEM 
medium supplemented with 10% fetal bovine serum 
(FBS). Fresh snap-frozen surgical specimens of tumor 
tissues from 79 EOC patients completely resected at the 
Queen Mary Hospital (Hong Kong) were consecutively 
collected. All the clinical specimens used in the present 
study were approved by the local institutional ethics 
committee (IRB: UW 11-298).
Plasmids and Drugs
The pmR-ZsGreen1-miR-199b-5p expressing 
construct (Forward- TCTCAGCCCAAGCTTCCGCTC, 
Reverse- AATGTGAGTGGATCCTTGCAC, 657bp) 
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was amplified and ligated into pmR-ZsGreen1 plasmid 
(Clontech, Mountain View, CA). The miRNA inhibitor 
targeting miR-199b-5p was purchased from Applied 
Biosystems (Product ID: AM10553, Applied Biosystems, 
Foster city, CA). The small interfere RNAs (Duplex 
Oligonucleotide) targeting JAG1 were purchased from 
IDT (Integrated DNA Technologies, Coralville, USA) 
(Supplementary Table 1). The JAG1 expressing plasmid 
(pCD-HA/JAG1) used for JAG1 expression was provided 
by Prof. Aly Karsan (British Columbia Cancer Research 
Centre, Canada), and pHES1-luc plasmid used for 
luciferase reporter assay was provided by Prof. Ryoichiro 
Kageyama (Kyoto University, Japan). Cisplatin (CDDP) 
was obtained from Calbiochem (Darmstadt, Germany) and 
was stocked at a concentration of 5 mg/ml at -20oC. 5-Aza-
2’-deoxycytidine (5-Aza-dC, Sigma Chemical Co., St 
Louis, MD, USA) at a concentration of 20 mM was stored 
at -20oC and freshly dissolved in culture medium before 
use. γ–secretase inhibitor (GSI XXI, Compound E, Merck, 
Darmstadt, Germany) was stocked at a concentration of 
1 mM at -20oC and freshly diluted to 10 μM in culture 
medium before use.
RNA isolation and quantitative real-time RT-PCR
Total RNA from cell lines and primary cancer tissue 
samples was prepared by TRIzol reagent (Invitrogen 
Life Technology). First-strand complementary DNA 
was synthesized and quantitative reverse transcription–
polymerase chain reaction was done using the miRCURY 
LNATM Universal RT miRNA PCR Kit (Product No. 
203450, Exiqon, Denmark) in an ABI 7500 system 
(Applied Biosystems). The miR-199b-5p probes were 
obtained from Exiqon (Product No. 204152). Each 
sample was performed in triplicate and normalized 
with human SNORD48 (Product No. 203903, Exiqon, 
Denmark). Bisulfite conversion, Methylation specific 
PCR (MS-PCR), Bisulfite Genomic Sequencing (BGS) 
and pyrosequencing analysis
Genomic DNA was extracted using the DNeasy 
Blood & Tissue Kit (QIAGEN, Valencia, CA) in ovarian 
cancer cell lines and cancer samples. The genomic DNA 
was then applied for bisulfite conversion using the EZ 
DNA Methylation-Gold Kit (Zymo Research, Orange, 
California, USA) according to the manufacturer’s 
protocol. The MS-PCR and BGS sequence was amplified 
by MyTaqTM HS Mix Reaction Buffer (Bioline, London, 
UK). The BGS amplified PCR products were cloned 
into the Topo TA vector (Bioline). Colonies were 
randomly picked for mini preparation and sequencing. 
The primers and PCR conditions for MSP and BGS 
are listed in (Supplementary Table 2.)  Pyrosequencing 
assays were designed using PSQ Assay Design Software 
(version 1.0.6, Biotage). The primers for amplifying the 
pyrosequencing region of miR-199b-5p were forward 
5’-  GGGAAGAGTTATGTAAGTGTTGGAAAGA-3’ 
and reverse 5’-AAAACTTCCCCTAACCCTTTC -3’. 
This assay amplifies a region of 357bp in advanced of 
miR-199b-5p (position -6,389 – -6,033), which includes 
ten CpG sites to be analyzed. These ten CpG sites were 
included in the BGS region.
Cell viability assays
Cell viability was evaluated by XTT assay and 
Focus formation assay. Approximately 2,000—3,000 cells 
were seeded into each well of a 96-well plate. The medium 
was refreshed 24 hours after cell seeding containing 
appropriate concentration of cisplatin or γ–secretase 
inhibitor. XTT was measured by Cell Proliferation Kit II 
(Roche Biosciences, Indianapolis, IN, USA) according 
to the manufacturer’s instructions. For focus formation 
assay, 5000 cells with stable expression of miRNA or 
control vector were seeded into 6-well plates. The medium 
was replaced with fresh medium containing appropriate 
concentration of cisplatin 24 hours after cell seeding 
and grew for about 14 days during which fresh medium 
containing cisplatin was refreshed for every 4 days. Cells 
were stained with 1% crystal violet (Sigma-Alrich, St. 
Louis, MO, USA). Numbers of foci were counted after 
the cells dried. Experiments were performed in triplicates 
and results were expressed as the mean ± SD.
Luciferase reporter assay
Luciferase constructs were made by ligating 
oligonucleotides containing the wild-type (WT) or 
mutant sites (MUT) of the 3’UTR of JAG1 gene (position 
135—141) into the multi-cloning site of the pmirGLO 
plasmid (Promega, Madison, WI) (Supplementary Table 
3). HEK293 cells were seeded into a 24-well plate and 
co-transfected with 100 ng pmirGLO-JAG1 plasmid, 
pmR-199b plasmid and pmR-ZsGreen1 empty vector 
for balance (400 ng in total), using LipofectamineTM 
2000 (Invitrogen). Luciferase activity was determined 
by the Dual-Luciferase Assay Kit (Promega) 48 h after 
transfection using a Fluorescence Spectrophotometer 
F-4500 (Promega).
Western Blot
Cells were harvested and lysed by RIPA Buffer 
(Sigma Chemical Co., St Louis, MD, USA). Samples 
containing equal amounts of protein were separated 
by SDS-PAGE and electroblotted onto Immobilon-P 
Transfer Membrane (Millipore Corporation, Bedford, 
MA). The membrane was blocked with 5% no-fat milk, 
followed by incubation with antibodies specific for 
anti-JAG1 (1:500, 28H8, Cell Signaling Technology, 
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Beverly, MA), anti-Notch1 (1:1000, C-20,sc-6014, Santa 
Cruz Biotechnology, Santa Cruz, CA) and anti-β-actin 
(1:5000, AC-74, Sigma Chemical Co), respectively. Blots 
were then incubated with goat anti-rabbit or anti-mouse 
secondary antibody conjugated to horseradish peroxidase 
(Amersham Pharmacia, Cleveland, OH) accordingly. The 
signals were captured by FUJI Medical X-Ray Film (Fuji) 
and developed by the FUJI system.
Immunohistochemistry (IHC) and in situ 
hybridization (ISH)
The commercial tissue array slide (OVC1021, 
Pantomics) was deparaffinized in xylene and rehydrated 
in alcohol, then immersed in sodium citrate buffer (pH6) 
and boiled in boiled water for 20 minutes. 0.3% hydrogen 
peroxidase (H2O2) was used to inhibit endogenous 
peroxidase. 10% normal rabbit serum was applied for 
blocking non-specific bindings for 45 minutes. Following 
this, slides were incubated with primary antibodies anti-
JAG1 monoclonal antibody (1:100) at predetermined 
dilutions at 4°C overnight. 0.1% Tween 20 (TBS-T) 
was used to wash the slides for three times. Staining 
was carried out following standard streptavidin-biotin-
peroidase complex method. Mayer’s hematoxylin was 
used for counterstained. Two independent investigators 
were invited to review counterstained slides. Scores were 
then given to the stained slides according to the intensity 
and the percentage of the stained tissues.
In situ hybridization (ISH) was performed to 
evaluate the miR-199b-5p expression in a commercial 
tissue array (OVC1021, Pantomics) using the miRCURY 
LNATM microRNA ISH Optimization Kit 5 (FFPE) 
(Exiqon, Vedbaek, Denmark).  In brief, the tissue array 
slide was deparaffinized and incubated with 20 μg/ml 
Proteinase-K for 40 minutes at 37°C. Following this, 
the slide was dehydrated and hybridized with specific 
miR-199b-5p probe (1:500) at 50°C overnight. After 
hybridization, the slide was incubated with anti-DIG 
reagent (sheep anti-DIG-AP at 1:400) for 60 minutes at 
room temperature and applied to freshly prepared AP 
substrate and incubated for 2 hours at 30°C in a dark, 
humidifying chamber. Finally, it was stained for nuclear 
counter and mounted with mounting medium (Eukitt®). 
The precipitate was allowed to settle overnight and the 
results were analyzed by light microscopy on the next day.
In vivo tumorigenicity
Ccancer cells with miR-199b-5p stably expression 
or vector control were injected subcutaneously into the 
right and left dorsal flank (2×106 per side), respectively, 
of BALB/c nude mice (5 mice per group). When the 
tumors were palpable, cisplatin (5mg/kg, Pharmachemie 
BV, Netherlands, Platosin, 1mg/ml) was injected into 
the mice in peritoneal every three days. Tumor size was 
observed by measuring the tumor volume calculating by 
the formula V=6/π*[(L+W)/2]3. Tumors were then excised 
after sacrifice. All animal experiments were approved by 
the Committee on the Use of Live Animals in Teaching 
and Research of The University of Hong Kong (CULATR 
2053-09),
Statistical analysis
Statistical analysis was carried out using SPSS 
14.0 (SPSS). Student’s t-test and the Mann–Whitney 
test were used. The results were expressed as mean ± 
SD. χ2 test or Fisher’s exact test was used to analyze the 
association of miR-199b-5p and JAG1 gene expression 
and clinicopathological parameters. Differences were 
considered significant when p ≤ 0.05.
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